Quintiles will promote respiratory drugs from Almirall in the UK, starting with the newly approved Eklira Genuair aclidinium bromide dry powder inhaler for the treatment of COPD. Quintiles performed some of the clinical study work for the product. Menarini will market the DPI in most of Europe as Bretaris Genuair.
Almirall UK General Manager Carlos Gallardo commented, “We are proud to bring the first product in a truly innovative respiratory franchise to the UK market. Our long-term alignment with Quintiles will help us to ensure that new therapeutic options are made available for COPD patients throughout the UK.”
Quintiles Managing Director, UK Commercial Solutions Robert Taylor said, “This partnership allows our talented and engaged workforce to drive success across the life cycle of Almirall’s respiratory products. We are excited to build upon our trusted relationship with Almirall by working to promote high potential compounds in the UK.”
Read the Quintiles press release.
